Duloxetine
Product Images NDC 0904-7045

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0904-7045). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

530e2d92 592c 488e 9a3b 1a61f09e6fc1 00

Duloxetine delayed-release capsules USP 30 mg unit dose package label from Major Pharmaceuticals. The label includes directions for pharmacists to dispense with a medication guide and states Rx only with 100 capsules in the package. Storage instructions and usage warnings are printed, along with the manufacturer and distributor information.*

FDA Label Image

530e2d92 592c 488e 9a3b 1a61f09e6fc1 01

Duloxetine delayed-release capsules USP 20 mg by Major Pharmaceuticals, shown on a rectangular label with NDC 0904-7043-61. The label indicates a unit dose package containing 100 capsules, with instructions for the pharmacist to dispense with a medication guide. Additional details include storage instructions, a caution to keep out of reach of children, and distributor information for Rising Health, LLC and Major Pharmaceuticals, Inc.*

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A Kaplan-Meier curve comparing the proportion of patients experiencing relapse over time (days) from randomization between placebo and duloxetine treatments. The graph features two lines: a dashed line for placebo and a solid line for duloxetine, indicating the relapse rates over approximately 240 days.*

FDA Label Image

Figure-2 (Duloxetine Fig2)

A line graph depicting the proportion of patients with relapse over time in days from randomization. It compares two treatments: Duloxetine and placebo, showing relapse rates increasing over a period of up to 250 days, with the Duloxetine group having a lower relapse proportion compared to placebo.*

FDA Label Image

Figure-3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, with lines representing the trends in patient improvement over varying pain improvement percentages.*

FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg given twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph shows a trend of higher patient improvement percentages for both Duloxetine dosing regimens versus placebo across increased pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine Fig5)

A graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg given twice daily, Duloxetine 60 mg given once daily, and placebo. The y-axis shows the percentage of patients improved, and the x-axis shows percent improvement in pain. Two Duloxetine dosing regimens show higher patient improvement percentages compared to placebo across all pain improvement levels.*

FDA Label Image

Figure 6 (Duloxetine Fig6)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Lines compare Duloxetine at 120 mg, 60 mg, and 20 mg once daily doses with placebo. The graph illustrates trends of patient improvement percentages decreasing as percent improvement in pain increases.*

FDA Label Image

Figure 7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo groups. The graph shows higher patient improvement percentages for Duloxetine across various percent improvement thresholds in pain.*

FDA Label Image

Figure 8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved over varying percent improvements in pain from baseline for Duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows a higher percentage of patients improved compared to placebo across the range.*

FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)

A line chart comparing the percentage of patients improved between placebo and Duloxetine 60/120 mg once daily across varying percent improvement in pain from baseline, ranging from greater than 0% to 100%. Duloxetine shows a higher percentage of patient improvement compared to placebo at most levels of pain improvement.*

FDA Label Image

Chemical Structure (Duloxetine Str)

Chemical structure diagram of Duloxetine hydrochloride showing its molecular composition including a naphthalene ring, a thiophene ring, and an amine group with hydrochloride salt.*

FDA Label Image

Carton Label (Image 02)

Packaging label for Duloxetine delayed-release capsules USP 60 mg by Major Pharmaceuticals. The label states it is unit dose, with 100 capsules per package. It includes usage instructions for pharmacists to dispense with medication guide, storage conditions, and distributor information for Rising Health LLC and Major Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.